KR910004185A - 세포독소 약제에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그 사용 - Google Patents

세포독소 약제에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그 사용 Download PDF

Info

Publication number
KR910004185A
KR910004185A KR1019900012981A KR900012981A KR910004185A KR 910004185 A KR910004185 A KR 910004185A KR 1019900012981 A KR1019900012981 A KR 1019900012981A KR 900012981 A KR900012981 A KR 900012981A KR 910004185 A KR910004185 A KR 910004185A
Authority
KR
South Korea
Prior art keywords
cytotoxin
compound
toremifene
compounds
cancer cells
Prior art date
Application number
KR1019900012981A
Other languages
English (en)
Other versions
KR0171893B1 (ko
Inventor
르웰린 해리스 아드리안
베이꼬 맛티 캉가스 로오리
윌리엄 드그레고리오 마이클
Original Assignee
르웰린 해리스 아드리안
베이꼬 맛티 캉가스 로오리
윌리엄 드그레고리오 마이클
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르웰린 해리스 아드리안, 베이꼬 맛티 캉가스 로오리, 윌리엄 드그레고리오 마이클 filed Critical 르웰린 해리스 아드리안
Publication of KR910004185A publication Critical patent/KR910004185A/ko
Application granted granted Critical
Publication of KR0171893B1 publication Critical patent/KR0171893B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음.

Description

세포독소 약제에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그 사용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 24시간 노출후 CHO-k1() 및 CHO-Adr() 세포계 내에서 토레미펜의 농도 증가의 효과를 나타낸 그래프이다. (닫힌 기호는 AAG(2㎎/㎖)의 부재를 나타내고, 열린 기호는 AAG의 존재를 나타낸다.)

Claims (11)

  1. 적어도 하나의 세포독소 화합물을 사용한 암치료에 있어서, 상기 세포독소 화합물에 대한 암세포의 다약제 내성의 역전을 위한 토레미펜, N-데메틸토레미펜, 4-히드록시 토레미펜 또는 이들의 제약학적으로 허용가능한 비-독성 염의 사용.
  2. 제1항에 있어서, 토레미펜의 사용.
  3. 제1항 또는 제2항에 있어서, 세포독소 화합물이 알킬화제, 항핵분열제, 항대사물, 플라티늄 화합물 또는 항생제인 사용.
  4. 제3항에 있어서, 항생제가 안트라시클린 항생물질인 사용.
  5. 제4항에 있어서, 안트라시클린항생물질이 독소루비신인 사용.
  6. (a) 토레미펜. N-데메틸-토레미펜, 4-히드록시토레미펜 또는 이들의 제약학적으로 허용가능한 비-독성염. (b) (a) 이외의 세포독소 화합물 및, (c) 제약학적으로 허용가능한 담체 또는 희석제로 구성된 제약학적 상승 조성물.
  7. 제6항에 있어서, (b)가 제3항 또는 제4항에서 정의된 바와같은 세포독소화합물인 조성물.
  8. 제6항에 있어서, (b)가 독소루비신인 화합물.
  9. 암치료에 있어서 동시적, 별도의 또는 연속적 사용을 위해 조합된 제제로서, (a)토레미펜, N-데메틸토레미펜 또는 4-히드록시 토레미펜 또는 이들의 제약학적으로 허용가능한 비-독성 염, 및 (b) (a) 이외의 세포독소 화합물을 함유한 생성물.
  10. 제9항에 있어서, (b)가 제3항 또는 제4항에서 정의된 바와 같은 세포독소화합물인 생성물.
  11. 제10항에 있어서, (b)가 독소루비신인 생성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900012981A 1989-08-23 1990-08-22 세포장해성 약물에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그를 포함하는 제약학적 조성물 KR0171893B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US397551 1989-08-23
US07/397,551 US4990538A (en) 1989-08-23 1989-08-23 Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs

Publications (2)

Publication Number Publication Date
KR910004185A true KR910004185A (ko) 1991-03-28
KR0171893B1 KR0171893B1 (ko) 1999-02-01

Family

ID=23571649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900012981A KR0171893B1 (ko) 1989-08-23 1990-08-22 세포장해성 약물에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그를 포함하는 제약학적 조성물

Country Status (11)

Country Link
US (1) US4990538A (ko)
EP (1) EP0415623A3 (ko)
JP (1) JP3186759B2 (ko)
KR (1) KR0171893B1 (ko)
AU (1) AU633954B2 (ko)
CA (1) CA2023630C (ko)
HU (1) HU215913B (ko)
IE (1) IE67639B1 (ko)
NZ (1) NZ234999A (ko)
PH (1) PH27064A (ko)
ZA (1) ZA906670B (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5114951A (en) * 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5162581A (en) * 1989-05-29 1992-11-10 Takaru Shuzo Co., Ltd. Crystalline deoxyspergualin, process for its preparation and suppository containing the same
GB8914040D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914060D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914062D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5114919A (en) * 1990-02-26 1992-05-19 Merck & Co., Inc. Adjuncts in cancer chemotherapy
ITRM910192A1 (it) * 1990-04-03 1991-10-04 American Cyanamid Co Metodo per invertire la resistenza a bisantrene mediata da p-glicoproteine.
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69304895T2 (de) * 1992-02-06 1997-02-06 Merrell Pharma Inc Aufhebung von Multi-Drug-Resistenz durch Tetraarylethylene
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US5840319A (en) * 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US5886049A (en) 1992-10-27 1999-03-23 Nippon Kayaku Kabushiki Kaisha Remedy for autoimmune diseases
EP0776661A1 (en) * 1992-10-27 1997-06-04 Nippon Kayaku Kabushiki Kaisha Combined preparation of antiestrogen and glucocorticoid for the treatment of autoimmune disease
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5432168A (en) * 1993-12-27 1995-07-11 University Of Manitoba Method of treatment of hormone-unresponsive metastatic prostate cancer
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5571687A (en) * 1994-06-07 1996-11-05 Duke University Modulators of multidrug resistance transporters
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
SK16642000A3 (sk) * 1998-05-07 2002-08-06 The University Of Tennessee Research Corporation Spôsob chemoprevencie rakoviny prostaty
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US6413534B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
EP1133996A4 (en) * 1998-11-26 2003-04-02 Teikoku Hormone Mfg Co Ltd DRUG COMPOSITIONS WITH PERIODIC ADMINISTRATION
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
WO2015089268A1 (en) * 2013-12-11 2015-06-18 University Of Massachusetts Compositions and methods for treating disease using salmonella t3ss effector protein (sipa)
CA2971216A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58836B1 (en) * 1984-08-02 1993-11-17 Labrie Fernand Pharmaceutical composition for combination therapy of hormone dependent cancers

Also Published As

Publication number Publication date
HU215913B (hu) 1999-03-29
EP0415623A3 (en) 1991-04-03
ZA906670B (en) 1991-06-26
IE903044A1 (en) 1991-02-27
PH27064A (en) 1993-02-01
IE67639B1 (en) 1996-04-17
US4990538A (en) 1991-02-05
AU633954B2 (en) 1993-02-11
JPH03163015A (ja) 1991-07-15
HU905276D0 (en) 1991-02-28
EP0415623A2 (en) 1991-03-06
JP3186759B2 (ja) 2001-07-11
CA2023630A1 (en) 1991-02-24
AU6113390A (en) 1991-02-28
KR0171893B1 (ko) 1999-02-01
NZ234999A (en) 1997-06-24
HUT58511A (en) 1992-03-30
CA2023630C (en) 2002-02-19

Similar Documents

Publication Publication Date Title
KR910004185A (ko) 세포독소 약제에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그 사용
CA1075157A (en) Veterinary composition containing mono-saccharide
ES2602956T3 (es) Composiciones de antibiótico para tratamiento de conjuntivitis
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
KR920002144A (ko) 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제
Bryan et al. Gentamicin accumulation by sensitive strains of Escherichia coli and Pseudomonas aeruginosa
Walsh et al. Clinical and microbiologic effects of single‐dose metronidazole or scaling and root planing in treatment of adult periodontitis
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
KR880004808A (ko) 항신생 활성을 갖는 제약 조성물
DE68909958D1 (de) Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung.
KR860003830A (ko) 가용화한 백금화합물 및 그 제조방법
BR9811137A (pt) Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
IL42313A (en) Pharmaceutical composition containing glycyrrhetinic acid for the treatment of oesophagitis
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
ES2142430T3 (es) Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral.
Palmer et al. Partial prevention by cyanide of selenium poisoning in rats
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
DE3777365D1 (de) Einspritzbare fertig brauchbare loesungen, die ein antracyclineglykosid als mittel gegen krebs enthalten.
US3577537A (en) Topical administration of vitamin b-12
KR870011135A (ko) 시스-6-(4-아세트아닐리도)-8,9-디메톡시-2-메틸-1,2,3,4,4a,10b- 헥사이드로-벤조〔c〕〔1,6〕 나프티리딘으로 구성된 약학적 조성물 및 그것의 용도
KR870001144A (ko) Nn-디메틸에틸옥사이드가 함유된 약제조성물 및 그의 생산방법
Zundel et al. Derivatives and analogues of benzaldehyde selectively cytotoxic to SV-40 transformed cells
KR900017599A (ko) 종양 치료용 약학 조성물
Princiotto et al. Absorption of oral chelated iron

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080922

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee